Sinovac Biotech Stock Rating Reaffirmed by Aegis (SVA)
Sinovac Biotech (NYSE:SVA)‘s stock had its “positive” rating reaffirmed by equities research analysts at Aegis in a research note issued to investors on Wednesday, Analyst Ratings Network.com reports.
Sinovac Biotech (NYSE:SVA) last issued its quarterly earnings data on Tuesday, November 12th. The company reported $0.04 earnings per share (EPS) for the quarter.
Sinovac Biotech Ltd. (NYSE:SVA) is a holding company that conducts its business in China through its 71.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.